Seek Labs Secures U.S. Patent for Innovative Isothermal Amplification Technology Designed to Advance Decentralized Molecular Diagnostics
Seek Labs, a private TechBio company focused on building programmable platforms to decode, program, and resolve diseases, has announced that the United States Patent and Trademark Office has granted U.S. Patent No. 12,618,795 B2. The newly issued patent protects the company’s proprietary Asymmetric Semi-Nested Isothermal Nucleotide Amplification technology, known as ANINA, which serves as a foundational assay design element within the company’s broader molecular amplification platform called Seek Amplification™.
The patent milestone represents a significant advancement for the company as it continues to develop next-generation molecular diagnostic technologies intended to support decentralized and accessible testing environments. By securing intellectual property protection for ANINA, Seek Labs strengthens its position in the rapidly evolving molecular diagnostics and TechBio landscape, where demand continues to grow for faster, simpler, and more portable diagnostic solutions.
The patented ANINA technology was designed to improve the performance and flexibility of isothermal nucleic acid amplification systems. Unlike conventional polymerase chain reaction (PCR)-based testing methods that typically require thermal cycling equipment and centralized laboratory infrastructure, isothermal amplification technologies can operate at a constant temperature. This approach has the potential to simplify workflows, reduce equipment complexity, and enable molecular testing outside of traditional laboratory settings.
Seek Labs’ Seek Amplification™ chemistry aims to leverage these advantages while also improving assay sensitivity, specificity, and operational efficiency. According to the company, the ANINA design architecture supports robust target amplification while maintaining compatibility with decentralized diagnostic platforms that can be deployed in a variety of healthcare and non-healthcare environments.
The newly patented technology could play an important role in expanding access to molecular diagnostics, particularly in settings where rapid and reliable testing is needed but access to sophisticated laboratory infrastructure is limited. Decentralized diagnostic systems have become increasingly important across healthcare, public health, infectious disease surveillance, and personalized medicine applications. The COVID-19 pandemic highlighted the critical importance of scalable and accessible diagnostic technologies capable of delivering accurate results closer to the point of need.
Seek Labs believes its patented chemistry platform can contribute to the growing movement toward distributed testing models that prioritize speed, convenience, and accessibility without compromising analytical performance. Molecular diagnostic systems utilizing isothermal amplification technologies are increasingly being explored for use in physician offices, pharmacies, outpatient clinics, remote healthcare facilities, and even home-testing environments.
The ANINA platform was specifically engineered to address some of the limitations commonly associated with traditional nucleic acid amplification methods. Semi-nested amplification approaches can improve analytical sensitivity and specificity by utilizing multiple amplification stages, while asymmetric amplification strategies can enhance the production of target nucleic acid strands suitable for downstream detection processes. By integrating these design principles into a single isothermal framework, Seek Labs has created a differentiated molecular amplification solution that may support a broad range of diagnostic applications.
The company’s Seek Amplification™ chemistry platform forms part of its larger mission to build programmable biological systems capable of decoding and resolving disease at scale. Seek Labs operates at the intersection of biotechnology, computational biology, and molecular engineering, areas that are increasingly converging to create more intelligent and adaptive healthcare technologies.
As molecular diagnostics continue to evolve, intellectual property protection has become a crucial strategic asset for companies developing novel amplification chemistries and assay platforms. The issuance of U.S. Patent No. 12,618,795 B2 provides Seek Labs with important protection for its core technological innovations while also supporting future commercial development efforts, potential partnerships, and platform expansion initiatives.
Industry interest in isothermal amplification technologies has accelerated in recent years due to their potential to complement or, in some cases, replace traditional PCR-based workflows in decentralized environments. While PCR remains the gold standard for many molecular testing applications, the requirement for expensive thermal cyclers and laboratory infrastructure can create barriers to broader adoption in resource-limited settings. Isothermal technologies offer a compelling alternative because they can simplify instrumentation and reduce turnaround times while maintaining strong analytical performance.
The decentralized diagnostics market is expected to continue expanding as healthcare systems increasingly prioritize rapid testing capabilities, real-time disease monitoring, and patient-centered care models. Emerging diagnostic platforms are being designed not only for infectious disease detection but also for oncology, genetic screening, antimicrobial resistance monitoring, and chronic disease management applications.
Seek Labs’ patented ANINA chemistry could support future development across multiple use cases where rapid nucleic acid detection is critical. The company’s programmable platform approach also suggests potential adaptability for detecting diverse biological targets, enabling broader scalability and customization across different disease areas.
In addition to healthcare applications, decentralized molecular testing technologies are gaining traction in areas such as environmental monitoring, food safety testing, veterinary diagnostics, and biodefense preparedness. Portable and scalable diagnostic solutions are increasingly viewed as essential tools for responding to emerging public health threats and improving global surveillance capabilities.
The patent award further validates Seek Labs’ ongoing research and development efforts aimed at advancing molecular biology technologies through innovative engineering and assay design. As competition intensifies within the molecular diagnostics sector, companies with differentiated intellectual property portfolios are expected to play a leading role in shaping the future of decentralized testing and programmable medicine.
Seek Labs continues to position itself as a technology-driven innovator within the broader TechBio ecosystem, where artificial intelligence, biology, and advanced computational systems are increasingly integrated to accelerate scientific discovery and healthcare innovation. The company’s focus on programmable diagnostic and disease-resolution platforms reflects a growing industry trend toward creating adaptive biological technologies capable of responding to rapidly changing clinical and public health needs.
With the issuance of this new U.S. patent, Seek Labs has added an important asset to its growing technology portfolio while reinforcing its commitment to developing scalable molecular diagnostic systems for the next generation of healthcare delivery. The ANINA-based Seek Amplification™ platform may ultimately contribute to a future where high-quality molecular testing becomes faster, more accessible, and more widely available across diverse care settings worldwide.
About SeekIt™
SeekIt is Seek Labs’ molecular point-of-care diagnostics platform designed to bring testing out of laboratories and to the point of care. Built for speed, accuracy, portability, and scalability, SeekIt integrates nucleic acid extraction and amplification as well as detection into a streamlined system that can support rapid deployment across clinical, public health, and field environments.
About Seek Labs
Every disease has a sequence. Seek Labs is a TechBio company building the systems to decode, program, and resolve diseases. At the core of this system is an AI-powered intelligence layer that analyzes and translates sequences into actionable data, informing two deployment layers across Sequence Ablation Therapeutics (SAT) and molecular detection. Together, these systems form a continuous loop where genomic data is decoded, translated into therapeutic and diagnostic outputs, and refined through real-world deployment.
Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah’s collaborative life sciences ecosystem. Together with our partners, we’re building faster, smarter solutions for the world’s most urgent health challenges.
